Coxibs and cardiovascular disease

New England Journal of Medicine

Volumn 351, Issue 17, 2004, Pages 1709-1711

  FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB; CYCLOOXYGENASE 2; ISOENZYME; ISOXAZOLE DERIVATIVE; LACTONE; MEMBRANE PROTEIN; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE; THROMBOXANE A2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; THROMBOSIS; ARTICLE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; METABOLISM; RISK; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; DRUG INDUSTRY; EPOPROSTENOL; GASTROINTESTINAL DISEASES; HUMANS; ISOENZYMES; ISOXAZOLES; LACTONES; MEMBRANE PROTEINS; NAPROXEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RISK; SULFONAMIDES; SULFONES; THROMBOXANE A2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 6044274282     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp048288     Document Type: Review

References (5)

1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
2. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-90.
3. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
4. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
5. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.